Merck & Co., Inc.
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Robert M. Davis
- Full Time Employees
- 73,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 2000 Galloping Hill Road Rahway NJ United States of America 07033
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Company News
Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.
Merck to Buy Verona Pharma in $10 Billion Deal
Merck to acquire Verona Pharma for $10 billion
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports
Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025
My Top 10 High-Yield Dividend Stocks For July 2025: One Yields 12%-Plus
Merck & Co.: A Pharma Titan At A Discount
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Merck Mercuriadis plots return with new Hipgnosis venture after market rebound
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025)
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
MRK Pins Hopes on New PAH Drug Winrevair Amid Looming Keytruda LOE
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
Top 15 High-Growth Dividend Stocks For July 2025
Trading Rotation Kicks Off 2nd Half of 2025
Top 10 High-Yield Dividend Stocks For July 2025
Dividend Yield Theory Says Merck Is A Buy
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?